CTOs on the Move

Promentis Pharmaceuticals

www.promentispharma.com

 
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Promentis Pharmaceuticals raised $26M on 03/30/2017

Similar Companies

Breas Medical

Breas was founded in 1991 in Gothenburg, Sweden and has become one of the global leaders in Home Mechanical Ventilation, Airway Clearance and Sleep therapy.

Sizewise

We offer bariatric and non-bariatric medical equipment including bed frames, therapeutic mattresses, and mobility items for patients of all ages.

Vision RT

Vision RT is the inventor of Surface Guided Radiation Therapy (SGRT) and produces a range of innovative solutions to improve radiation therapy.

Cardiovascular Systems

Cardiovascular Systems, Inc. is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Morel Company

A new, innovative product that allows a single caregiver to reposition a patient up in bed in less than ten seconds with the simple push of a button. Learn more here.